Developing an Inflammatory Bowel Disease Specific Frailty Assessment

  • Research type

    Research Study

  • Full title

    Developing an Inflammatory Bowel Disease Specific Frailty Assessment Tool

  • IRAS ID

    318421

  • Contact name

    Christian Selinger

  • Contact email

    christian.selinger@web.de

  • Sponsor organisation

    Leeds teaching Hospitals NHS Trust

  • Clinicaltrials.gov Identifier

    PR Committee, 23/PR/1305

  • Duration of Study in the UK

    0 years, 7 months, 1 days

  • Research summary

    We are treating growing numbers of older inflammatory bowel disease (IBD) patients. These lifelong diseases cause inflammation in the gut affecting 1% of the UK population with 25% being aged over 65. However, older patients are often excluded from clinical trials but may experience more serious problems from IBD medications like infections, cancer, and hospitalisation. This may explain why they are sometimes given less effective treatments leading to poor control of their condition.

    As we age our bodies change and can lose their inbuilt reserves, leading to frailty. Older people with frailty can experience dramatic health changes because of small problems like new medications or infections. Unfortunately, the importance of frailty in IBD has not been recognised until recently. Doctors use ‘frailty assessment tools’ to identify frail patients. The trouble with using these for IBD is that some symptoms associated with frailty are also IBD symptoms, so IBD patients could be wrongly labelled as frail. We aim to develop an IBD frailty assessment tool to help doctors and patients understand who is more likely to become unwell after starting advanced IBD treatments, helping everyone make the best treatment decisions.

    We have summarised the current research on IBD and frailty and analysed data exploring how frailty before starting IBD treatment is associated with hospitalisation. We plan to discuss the results with patients and clinicians to develop a frailty assessment tool. We will then see how practical this tool is in clinic by testing it with around forty patients about to start IBD treatments. We will use interviews to understand how acceptable and manageable it is for patients. All patients involved will be invited to a meeting to help us understand which parts are most important to them and guide us how to tell other patients about our results.

  • REC name

    London - Fulham Research Ethics Committee

  • REC reference

    23/PR/1305

  • Date of REC Opinion

    19 Dec 2023

  • REC opinion

    Further Information Favourable Opinion